<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409627</url>
  </required_header>
  <id_info>
    <org_study_id>INXN-4001-001</org_study_id>
    <nct_id>NCT03409627</nct_id>
  </id_info>
  <brief_title>Novel INXN-4001 Triple Effector Plasmid in Heart Failure</brief_title>
  <official_title>A Phase I, Open Label, Safety Study of INXN-4001 Delivered Via Retrograde Coronary Sinus Infusion in Patients With an Outpatient Left Ventricular Assist Device (LVAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xogenex, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Precigen, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xogenex, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety of retrograde coronary sinus infusion of a novel triple-effector
      plasmid (INXN-4001) in outpatient LVAD recipients as assessed by incidence of all study
      intervention - related adverse events occurring up to 6 months post-treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety and feasibility of INXN-4001</measure>
    <time_frame>6 months</time_frame>
    <description>As assessed by incidence of all study intervention-related adverse events occurring up to 6 months post- treatment intervention-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wean tolerability following treatment with INXN-4001</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement in 6 minute walk duration and distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life following treatment with INXN-4001</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Kansas City Cardiomyopathy Questionnaire responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of biosensor activity tracking</measure>
    <time_frame>12 months</time_frame>
    <description>Ability to collect daily activity level as measured by wearable biosensor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall safety of INXN-4001</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of cardiac-specific adverse events and study intervention-related serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart-Assist Device</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single infusion of INXN-4001, Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single infusion of INXN-4001, Dose 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INXN-4001</intervention_name>
    <description>Retrograde coronary sinus infusion of triple effector plasmid (INXN-4001)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adult patients with a stable LVAD implanted for end-stage heart
             failure

          -  Must be managed in an outpatient setting and on stable medication regimen

        Exclusion Criteria:

          -  Women who are pregnant or nursing

          -  Patients who have been on another clinical trial for heart failure in the last 90
             days, or have received any stem cell or gene therapy within the previous year.

          -  Patient is not able to complete a Six Minute Walk Test or unable to tolerate an LVAD
             wean in the past 3 months

          -  Patient has an active infection requiring systemic antibiotics or an autoimmune
             disease requiring systemic immunosuppressants

          -  Patient has a history of arrhythmia, uncontrolled diabetes, diabetic retinopathy,
             systemic lupus erythematosus, macular degeneration, hyper-coagulation, or stroke

          -  Patient has had a myocardial infarction related to ischemia within the past 30 days

          -  Patient has had certain prior surgeries such as organ transplant, cardiac
             transplantation, left ventricle reduction surgery, or cardiomyoplasty

          -  Patient has infectious disease, such as hepatitis B or C, or human immunodeficiency
             virus (HIV)

          -  Patient has a history of cancer within the past 3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Bull, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich Jorde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Fisher, PhD</last_name>
    <phone>301-556-9824</phone>
    <email>sfisher@precigentherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Sarver Heart Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine MacDonald, BScN, MBA</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>retrograde coronary sinus infusion</keyword>
  <keyword>DNA</keyword>
  <keyword>non-viral</keyword>
  <keyword>triple effector plasmid</keyword>
  <keyword>gene therapy</keyword>
  <keyword>regenerative medicine</keyword>
  <keyword>non-stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

